Last reviewed · How we verify
Ustekinumab (90 mg)
Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation.
Ustekinumab is a monoclonal antibody that targets and binds to the p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby inhibiting their activity and reducing inflammation. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Moderate to severe Crohn's disease.
At a glance
| Generic name | Ustekinumab (90 mg) |
|---|---|
| Also known as | Stelara, CNTO 1275, STELARA |
| Sponsor | Janssen Scientific Affairs, LLC |
| Drug class | IL-12/23 inhibitor |
| Target | p40 subunit of IL-12 and IL-23 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to the p40 subunit, ustekinumab prevents the formation of the IL-12 and IL-23 heterodimers, which are key cytokines involved in the inflammatory response. This leads to a decrease in the production of pro-inflammatory cytokines and a reduction in inflammation. Ustekinumab is used to treat various inflammatory conditions, including psoriasis, psoriatic arthritis, and Crohn's disease.
Approved indications
- Moderate to severe plaque psoriasis
- Psoriatic arthritis
- Moderate to severe Crohn's disease
Common side effects
- Upper respiratory tract infection
- Nausea
- Headache
- Fatigue
- Injection site reaction
Key clinical trials
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
- Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
- Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
- Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease (PHASE4)
- Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
- De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis (PHASE4)
- The Association Between TNFSF4 Polymorphism and CD
- A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ustekinumab (90 mg) CI brief — competitive landscape report
- Ustekinumab (90 mg) updates RSS · CI watch RSS
- Janssen Scientific Affairs, LLC portfolio CI